Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463164 | 0.82 | TDP1 (0.37) | — | |
| SCHEMBL11988782 | 0.82 | L3MBTL1 (0.51) | HPGDCA12CA1CA2CA9 | |
| SCHEMBL11988810 | 0.82 | TSHR (0.36) | GAALCK | |
| SCHEMBL12374471 | 0.80 | FOLH1 (0.46) | — | |
| SCHEMBL21122927 | 0.79 | P2RY12 (0.35) | GAAHPGDCA12CA1CA2 | |
| SCHEMBL12374464 | 0.79 | TUBB4A (0.33) | GAAHPGD | |
| SCHEMBL11988266 | 0.79 | L3MBTL1 (0.41) | HPGDCA12CA1CA2CA9 | |
| SCHEMBL21065294 | 0.79 | NAALAD2 (0.47) | HPGD | |
| SCHEMBL12462485 | 0.79 | NAALAD2 (0.47) | HPGD | |
| SCHEMBL13051269 | 0.78 | GAA (0.38) | GAAHPGDCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141368-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | L'OREAL (FR) | 2021-10-12 | — | — | US | disclosed |
| US-10813866-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | L'OREAL (FR) | 2020-10-27 | — | — | US | disclosed |
| US-8575341-B2 | Cosmetic composition, cosmetic treatment method, and compound | L'OREAL (FR) | 2013-11-05 | — | — | US | disclosed |
| US-8575341-B2 | Cosmetic composition, cosmetic treatment method, and compound | L'OREAL (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20130017162-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | L'OREAL (FR) | 2013-01-17 | — | — | US | disclosed |
| US-20130017162-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | L'OREAL (FR) | 2013-01-17 | — | — | US | disclosed |
| US-20110189118-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND | L'OREAL (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110189118-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND | L'OREAL (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2011083243-A1 | COSMETIC TREATMENT METHODS AND KIT | L'OREAL (FR) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011080494-A2 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | L'OREAL (FR) | 2011-07-07 | — | — | WO | disclosed |
| WO-2010001041-A2 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND | L'OREAL (FR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017162-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND | KRT18, KIT, TYR | USP2 1842/4885GAA 2948/4885HPGD 1893/4885 |
| US-20110189118-A1 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, AND COMPOUND | KRT18, MC1R, C1R | USP2 2648/4885GAA 4592/4885HPGD 1269/4885 |
| US-10813866-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | KRT18, KIT, TYR | USP2 1842/4885GAA 2948/4885HPGD 1893/4885 |
| US-11141368-B2 | Cosmetic composition, cosmetic treatment method, kit, and compound | KRT18, KIT, TYR | USP2 1842/4885GAA 2948/4885HPGD 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.